Novel antioxidant technology for prostate cancer chemoprevention and treatment

Steven Attia, George Wilding

Research output: Contribution to journalArticle

Abstract

The mechanisms underlying prostate carcinogenesis are not firmly elucidated. An exciting area of research in this regard asks whether prostate cancer results from the consequences of lifelong exposure of prostate tissue to oxidative stress. This article reviews the laboratory-based literature on oxidative stress and its possible role in prostate carcinogenesis. The progression of clinical studies focusing on the relationship between antioxidant supplementation and risk of developing prostate cancer are discussed, along with the patent literature since 2003 involving novel antioxidant technology applicable to prostate cancer prevention and treatment. In particular, recently published in vitro experiments with a novel α-tocopherol analogue, 2,2,5,7,8-pentamethyl-6-chromonal, which characterised its unique spectrum of antioxidant and antiandrogen properties in prostate cancer cell lines, is discussed. In addition, recent patent applications and supporting findings from the literature surrounding: i) cisplatin tocopherol compounds; ii) coix seed soft capsules with vitamin E; iii) vitamin E succinate (α-tocopheryl succinate); iv) lycopene preparations with other carotenoids; v) compounds of the ginger family; vi) novel aryl-carbaldehyde oxime derivatives; vii) novel phenyl quinoline derivatives; and viii) resveratrol, its derivatives and preparations thereof are dicussed as they relate to prostate cancer chemoprevention and treatment.

Original languageEnglish (US)
Pages (from-to)1255-1267
Number of pages13
JournalExpert Opinion on Therapeutic Patents
Volume16
Issue number9
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Chemoprevention
Prostatic Neoplasms
cancer
Antioxidants
Tocopherols
Technology
Prostate
Succinic Acid
patent
Coix
Carcinogenesis
Oxidative Stress
Ginger
Literature
Therapeutics
Androgen Antagonists
Oximes
Patents
Carotenoids
Vitamin E

Keywords

  • α-tocopherol
  • Aryl-carbaldehyde oxime
  • Carotenoid
  • Chemoprevention
  • Cisplatin tocopherol
  • Coix seed
  • Lycopene
  • Oxidative stress
  • PMCol
  • Reactive oxygen species
  • Resveratrol
  • Vitamin E succinate

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law

Cite this

Novel antioxidant technology for prostate cancer chemoprevention and treatment. / Attia, Steven; Wilding, George.

In: Expert Opinion on Therapeutic Patents, Vol. 16, No. 9, 09.2006, p. 1255-1267.

Research output: Contribution to journalArticle

@article{902dcac59d4c48f99a04b3c850659a94,
title = "Novel antioxidant technology for prostate cancer chemoprevention and treatment",
abstract = "The mechanisms underlying prostate carcinogenesis are not firmly elucidated. An exciting area of research in this regard asks whether prostate cancer results from the consequences of lifelong exposure of prostate tissue to oxidative stress. This article reviews the laboratory-based literature on oxidative stress and its possible role in prostate carcinogenesis. The progression of clinical studies focusing on the relationship between antioxidant supplementation and risk of developing prostate cancer are discussed, along with the patent literature since 2003 involving novel antioxidant technology applicable to prostate cancer prevention and treatment. In particular, recently published in vitro experiments with a novel α-tocopherol analogue, 2,2,5,7,8-pentamethyl-6-chromonal, which characterised its unique spectrum of antioxidant and antiandrogen properties in prostate cancer cell lines, is discussed. In addition, recent patent applications and supporting findings from the literature surrounding: i) cisplatin tocopherol compounds; ii) coix seed soft capsules with vitamin E; iii) vitamin E succinate (α-tocopheryl succinate); iv) lycopene preparations with other carotenoids; v) compounds of the ginger family; vi) novel aryl-carbaldehyde oxime derivatives; vii) novel phenyl quinoline derivatives; and viii) resveratrol, its derivatives and preparations thereof are dicussed as they relate to prostate cancer chemoprevention and treatment.",
keywords = "α-tocopherol, Aryl-carbaldehyde oxime, Carotenoid, Chemoprevention, Cisplatin tocopherol, Coix seed, Lycopene, Oxidative stress, PMCol, Reactive oxygen species, Resveratrol, Vitamin E succinate",
author = "Steven Attia and George Wilding",
year = "2006",
month = "9",
doi = "10.1517/13543776.16.9.1255",
language = "English (US)",
volume = "16",
pages = "1255--1267",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Novel antioxidant technology for prostate cancer chemoprevention and treatment

AU - Attia, Steven

AU - Wilding, George

PY - 2006/9

Y1 - 2006/9

N2 - The mechanisms underlying prostate carcinogenesis are not firmly elucidated. An exciting area of research in this regard asks whether prostate cancer results from the consequences of lifelong exposure of prostate tissue to oxidative stress. This article reviews the laboratory-based literature on oxidative stress and its possible role in prostate carcinogenesis. The progression of clinical studies focusing on the relationship between antioxidant supplementation and risk of developing prostate cancer are discussed, along with the patent literature since 2003 involving novel antioxidant technology applicable to prostate cancer prevention and treatment. In particular, recently published in vitro experiments with a novel α-tocopherol analogue, 2,2,5,7,8-pentamethyl-6-chromonal, which characterised its unique spectrum of antioxidant and antiandrogen properties in prostate cancer cell lines, is discussed. In addition, recent patent applications and supporting findings from the literature surrounding: i) cisplatin tocopherol compounds; ii) coix seed soft capsules with vitamin E; iii) vitamin E succinate (α-tocopheryl succinate); iv) lycopene preparations with other carotenoids; v) compounds of the ginger family; vi) novel aryl-carbaldehyde oxime derivatives; vii) novel phenyl quinoline derivatives; and viii) resveratrol, its derivatives and preparations thereof are dicussed as they relate to prostate cancer chemoprevention and treatment.

AB - The mechanisms underlying prostate carcinogenesis are not firmly elucidated. An exciting area of research in this regard asks whether prostate cancer results from the consequences of lifelong exposure of prostate tissue to oxidative stress. This article reviews the laboratory-based literature on oxidative stress and its possible role in prostate carcinogenesis. The progression of clinical studies focusing on the relationship between antioxidant supplementation and risk of developing prostate cancer are discussed, along with the patent literature since 2003 involving novel antioxidant technology applicable to prostate cancer prevention and treatment. In particular, recently published in vitro experiments with a novel α-tocopherol analogue, 2,2,5,7,8-pentamethyl-6-chromonal, which characterised its unique spectrum of antioxidant and antiandrogen properties in prostate cancer cell lines, is discussed. In addition, recent patent applications and supporting findings from the literature surrounding: i) cisplatin tocopherol compounds; ii) coix seed soft capsules with vitamin E; iii) vitamin E succinate (α-tocopheryl succinate); iv) lycopene preparations with other carotenoids; v) compounds of the ginger family; vi) novel aryl-carbaldehyde oxime derivatives; vii) novel phenyl quinoline derivatives; and viii) resveratrol, its derivatives and preparations thereof are dicussed as they relate to prostate cancer chemoprevention and treatment.

KW - α-tocopherol

KW - Aryl-carbaldehyde oxime

KW - Carotenoid

KW - Chemoprevention

KW - Cisplatin tocopherol

KW - Coix seed

KW - Lycopene

KW - Oxidative stress

KW - PMCol

KW - Reactive oxygen species

KW - Resveratrol

KW - Vitamin E succinate

UR - http://www.scopus.com/inward/record.url?scp=33748704932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748704932&partnerID=8YFLogxK

U2 - 10.1517/13543776.16.9.1255

DO - 10.1517/13543776.16.9.1255

M3 - Article

VL - 16

SP - 1255

EP - 1267

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 9

ER -